Urogen Pharma (NASDAQ:URGN) Downgraded to “Sell” Rating by Wall Street Zen

Wall Street Zen lowered shares of Urogen Pharma (NASDAQ:URGN) from a hold rating to a sell rating in a report issued on Saturday morning.

Other equities research analysts also recently issued reports about the stock. Piper Sandler started coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 price target for the company. D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of Urogen Pharma in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th. Finally, HC Wainwright cut their price objective on Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $32.00.

Urogen Pharma Trading Up 0.1%

URGN stock opened at $16.95 on Friday. The firm has a 50 day moving average of $18.53 and a 200-day moving average of $14.06. Urogen Pharma has a 12-month low of $3.42 and a 12-month high of $21.71. The company has a market cap of $784.17 million, a price-to-earnings ratio of -5.11 and a beta of 1.00.

Urogen Pharma (NASDAQ:URGN) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.23). Urogen Pharma had a negative net margin of 164.44% and a negative return on equity of 97,487.15%. The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. Sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Urogen Pharma news, CFO Chris Degnan sold 2,203 shares of Urogen Pharma stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the completion of the sale, the chief financial officer directly owned 2,280 shares of the company’s stock, valued at approximately $38,418. The trade was a 49.14% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 1,520 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the sale, the general counsel directly owned 43,305 shares of the company’s stock, valued at $827,558.55. This represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 27,265 shares of company stock valued at $502,236. Company insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors have recently made changes to their positions in the stock. Osaic Holdings Inc. grew its stake in shares of Urogen Pharma by 491.2% during the 2nd quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after buying an additional 3,070 shares during the period. CWM LLC grew its stake in shares of Urogen Pharma by 6,047.1% during the 1st quarter. CWM LLC now owns 5,225 shares of the company’s stock valued at $58,000 after buying an additional 5,140 shares during the period. GAMMA Investing LLC grew its stake in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company’s stock valued at $83,000 after buying an additional 7,392 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Urogen Pharma by 422.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock valued at $94,000 after buying an additional 5,571 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Urogen Pharma by 9.4% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock valued at $127,000 after buying an additional 797 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.